Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers
- PMID: 12414850
- DOI: 10.1210/jc.2002-020727
Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers
Abstract
In a 5-yr randomized prospective study we examined the treatment effect of estrogen replacement therapy/hormone replacement therapy (ERT/HRT), calcitriol, ERT/HRT and calcitriol, or placebo for 3 yr and the effect of discontinuation of therapy for 2 more yr on bone mineral density (BMD), calciotropic hormones, markers of bone remodeling, and calcium absorption in 489 elderly women. The treatment phase of the study was double-blinded. After discontinuing therapy for 2 yr, there was rapid bone loss in all 3 treatment groups, and most of the decrease in BMD occurred in the first year. In the ERT/HRT group, spine BMD increased 5.5% in yr 3, decreased 3.2% in yr 4, and decreased 0.7% in yr 5; femoral neck BMD increased 3.7% in yr 3, decreased 2.5% in yr 4, and decreased 0.4% in yr 5; total body BMD increased 2.1% in yr 3, decreased 1.4% in yr 4, and decreased 0.6% in yr 5. In the combination group, spine BMD increased 7.1% in yr 3, decreased 4.3% in yr 4, and decreased 0.3% in yr 5; femoral neck BMD increased 4.5% in yr 3, decreased 3.0% in yr 4, and decreased 0.01% in yr 5; total body BMD increased 2.2% in yr 3, decreased 1.5% in yr 4, and decreased 0.6% in yr 5. In the calcitriol group, spine BMD increased 1.8% in yr 3, decreased 1.8% in yr 4, and showed no change in yr 5; femoral neck BMD increased 0.2% in yr 3, decreased 0.2% in yr 4, and decreased 0.6% in yr 5; total body BMD decreased 0.4% in yr 3, decreased 0.6% in yr 4, and decreased 0.4% in yr 5. Compared with placebo, all treated groups at yr 5 had significantly higher total body BMD; only the combination group had significantly higher spine BMD (3.4%; P < 0.001) and total hip BMD (2.4%; P < 0.01.) compared with the placebo group. Compared with baseline, only spine BMD in the combination group was significantly higher (2.6%; P < 0.001) at yr 5. The increase in calcium absorption and the decrease in serum PTH levels in the calcitriol groups were reversed after discontinuation of treatment, and the decrease in bone markers was reversed in the hormone-treated groups. These results suggest that discontinuation of ERT/HRT and/or calcitriol therapy in elderly women leads to a decrease in much of the BMD gained on treatment; however, in the combination group there was a statistically significant residual effect on spine BMD.
Similar articles
-
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28. doi: 10.1210/jcem.86.8.7703. J Clin Endocrinol Metab. 2001. PMID: 11502787 Clinical Trial.
-
Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.J Clin Endocrinol Metab. 1997 Aug;82(8):2476-82. doi: 10.1210/jcem.82.8.4177. J Clin Endocrinol Metab. 1997. PMID: 9253321 Clinical Trial.
-
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25. doi: 10.1210/jcem.86.3.7294. J Clin Endocrinol Metab. 2001. PMID: 11238495 Clinical Trial.
-
Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.J Bone Miner Res. 1998 Sep;13(9):1431-8. doi: 10.1359/jbmr.1998.13.9.1431. J Bone Miner Res. 1998. PMID: 9738515 Clinical Trial.
-
Decreased bone mineral density and reproductive axis dysfunction: more than oestrogen.Neth J Med. 2020 Mar;78(2):50-54. Neth J Med. 2020. PMID: 32332177 Review.
Cited by
-
Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization.Menopause. 2011 Nov;18(11):1172-7. doi: 10.1097/gme.0b013e31821b01c7. Menopause. 2011. PMID: 21775911 Free PMC article.
-
Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.Cochrane Database Syst Rev. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4. Cochrane Database Syst Rev. 2014. PMID: 24729336 Free PMC article.
-
Serum vitamin D metabolites and intestinal calcium absorption efficiency in women.Am J Clin Nutr. 2010 Oct;92(4):835-40. doi: 10.3945/ajcn.2010.29553. Epub 2010 Jul 21. Am J Clin Nutr. 2010. PMID: 20660223 Free PMC article.
-
The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.Br J Clin Pharmacol. 2016 Sep;82(3):583-623. doi: 10.1111/bcp.12975. Epub 2016 Jun 13. Br J Clin Pharmacol. 2016. PMID: 27077231 Free PMC article.
-
Hormone therapy for preventing cardiovascular disease in post-menopausal women.Cochrane Database Syst Rev. 2015 Mar 10;2015(3):CD002229. doi: 10.1002/14651858.CD002229.pub4. Cochrane Database Syst Rev. 2015. PMID: 25754617 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical